Letrozole Sanoswiss

Letrozole, the active ingredient in Letrozole Sanoswiss, is an aromatase inhibitor presented as a tablet for oral use. It works by reversibly inhibiting the aromatase enzyme, decreasing peripheral conversion of androgens to estrogens. This reduction in estrogen levels is essential for managing hormone receptor‑positive breast cancer in postmenopausal women, where estrogen can drive tumor proliferation. The drug is approved in the European Union and is incorporated into endocrine therapy regimens.

GNH USA supplies Letrozole Sanoswiss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is used in endocrine therapy for hormone‑dependent breast cancer. - Hormone receptor‑positive early‑stage breast cancer (postmenopausal): reduces risk of recurrence by lowering estrogen stimulation of residual tumor cells. - Hormone receptor‑positive metastatic breast cancer (postmenopausal): slows disease progression through sustained estrogen suppression. - Adjuvant therapy after surgery for postmenopausal breast cancer: improves disease‑free survival by maintaining low estrogen levels.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature and sweating. - Joint and muscle pain: arthralgia or myalgia affecting mobility. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Osteoporosis or bone fracture: decreased bone mineral density leading to fractures. - Severe liver injury: marked elevation of transaminases or hepatic failure. - Cardiovascular events: thrombosis or myocardial infarction.

When prescribing Letrozole, clinicians should consider several safety and handling precautions. - Assess bone health: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. - Monitor liver function: perform periodic liver enzyme tests during therapy. - Evaluate cardiovascular risk: screen for hypertension, hyperlipidemia, and prior thrombotic events. - Avoid use in premenopausal women: drug is ineffective unless ovarian suppression is achieved. - Review drug interactions: check concomitant medications that may affect estrogen levels. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma concentrations. - Estrogen‑containing hormone therapy (e.g., conjugated estrogens, oral contraceptives): counteracts the intended estrogen suppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): may increase letrozole levels, requiring monitoring for toxicity. - Tamoxifen: combined use may affect hormonal balance and should be evaluated by the oncologist. - Warfarin: letrozole may enhance anticoagulant effect; monitor INR closely.